Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Forte Biosciences (FBRX) EBIT Margin (2016 - 2020)

Forte Biosciences (FBRX) has disclosed EBIT Margin for 5 consecutive years, with 268.12% as the latest value for Q1 2020.

  • Quarterly EBIT Margin rose 18772368.0% to 268.12% in Q1 2020 from the year-ago period, while the trailing twelve-month figure was 6121.96% through Dec 2020, up 6097751.0% year-over-year, with the annual reading at 11288.89% for FY2019, 1103466.0% down from the prior year.
  • EBIT Margin for Q1 2020 was 268.12% at Forte Biosciences, up from 17377.78% in the prior quarter.
  • The five-year high for EBIT Margin was 1706.2% in Q3 2016, with the low at 212311.11% in Q4 2018.
  • Average EBIT Margin over 5 years is 60441.61%, with a median of 7600.0% recorded in 2019.
  • The sharpest move saw EBIT Margin tumbled -14414705bps in 2018, then soared 19493333bps in 2019.
  • Over 5 years, EBIT Margin stood at 1527.39% in 2016, then crashed by -7097bps to 106870.0% in 2017, then tumbled by -99bps to 212311.11% in 2018, then skyrocketed by 92bps to 17377.78% in 2019, then surged by 102bps to 268.12% in 2020.
  • According to Business Quant data, EBIT Margin over the past three periods came in at 268.12%, 17377.78%, and 7600.0% for Q1 2020, Q4 2019, and Q3 2019 respectively.